VERICEL CORP (VCEL)
Health Care · Biotechnology · NASDAQ
Vericel is a commercial-stage biotechnology company that develops and markets autologous cell therapies for the treatment of severe burns and cartilage damage in the knee.
What VERICEL CORP does
Vericel is a commercial-stage biopharmaceutical company focused on the development and marketing of advanced cell therapy and regenerative medicine products. The company's primary offerings address the treatment of patients with severe burns and sports-related cartilage injuries through specialized cell-based treatments. Vericel operates integrated manufacturing and commercialization infrastructure to support its proprietary therapeutic pipeline.
Themes: regenerative medicine, cell therapy, orthopedics, burn care
Fundamentals
- Price$40.05 as of 2026-10-08 close
- Market cap$2.1B as of 2026-07-24 (share count; price 2026-10-08)
- 1-year return+17.3% 2025-10-08 close $34.13 → 2026-10-08 close $40.05
- P/E95.88 as of 2026-10-08
- Net margin+6.0% FY2025, SEC XBRL
- Gross margin+74.4% FY2025, SEC XBRL
- ROE+4.7% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Revenue growth (YoY)+22.9% as of 2026-09-02
- Revenue CAGR (3y)+18.9% SEC XBRL
- Beta1.11 as of 2026-09-02
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How VCEL compares in its sector
- price-to-earnings ratiotop 25% 185 covered Health Care peers, as of 2026-10-08
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- gross margintop 25% 189 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
VCEL is not currently in any published Top 10 list. Its scores are below.
Top 10 score
48.5 #822 of 1,379 scored · #98 of 151 in Health Care
Growth 81st (3-year revenue CAGR 18.9%, revenue growth year over year 23%) and financial health 67th (debt to equity 0, free cash flow margin 9%); weakest is valuation (21st, price to earnings 95.9, price to book 5.5).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How VERICEL CORP looks technically
VERICEL CORP (VCEL) is trading 4.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 74 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 4 trading days ago. It is 18.8% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move.
Trend
9
| Distance from the 200-day | it is trading 4.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +4.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $41.70 | $41.70 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $38.34 | $38.34 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a completed five-part downward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes below 38.21. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave downward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 74 trading days ago — a "golden cross", a bullish long-term signal | 74 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 4.5% above | +4.5% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 16.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30) | 47.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($38.21 to $41.45) — its "stochastic" reading is 57 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 56.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 17 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $49.32 | $49.32 |
|---|---|---|
| From the 52-week high | it is 18.8% below its 52-week high (its highest price of the past year) | -18.8% |
| Above the 52-week low | it is 38.3% above its 52-week low (its lowest price of the past year) | +38.3% |
| Below the 52-week high | it is 18.8% below its highest point of the past year | 18.8% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day low about 21 trading days ago | 21 sessions |
| All-time high | its highest closing price on record is $569.60 (set on 2005-07-13) | $569.60 |
| Given back of the 52-week move | over the past year its closes ranged ($29.34 to $48.31), and it has given back roughly a third of its rise from last year’s low — 44% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $35.98 to $36.59. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 43.5% |
| From the all-time high | it is 93.0% below its all-time high | -93.0% |
| Nearest price level | it is trading 2.0% below a resistance level at $40.86 — a price it turned at twice since 2026-05-07, most recently on 2026-09-16. Since 2024-10-08 it has 9 such levels below the current price and 9 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.0% |
| All-time low | its lowest closing price on record is $1.69 (set on 2015-11-17) | $1.69 |
| Above the all-time low | it is 2269.8% above its all-time low | +2,270% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 0th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.34 between its high and its low — about 3.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.34 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $38.67 and $41.13 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $38.67 – $39.90 – $41.13 |
| Typical daily range (% of price) | its price moves about 3.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.3% |
| Stretch from the 200-day average | it is trading 1.3 daily ranges above its 200-day average price (4.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.45× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|---|---|
| Gap filled | a 2.0% gap down opened on 2026-08-04 has been "filled" 46 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 46 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 1.4 percentage points (the stock gained 2.5% while the market gained 1.0%) | +1.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 18.7 percentage points (the stock lost 14.8% while the market gained 3.8%) | -18.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 0.1 percentage points (the stock gained 17.5% while the market gained 17.5%) | +0.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 2.4 percentage points (the stock gained 17.3% while the market gained 15.0%) | +2.4% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 6.6% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 3.2% of the share price. | -6.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 5% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $38.25 — a volume-weighted average of daily closes over 189 sessions, not a true tick-by-tick VWAP. | +4.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% below the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is under water. That average is $41.70 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -4.0% |
Price levels it has turned at before
VCEL last closed at $40.05 on 2026-10-08. Since 2024-10-08 it has turned at 9 prices below its last close and 9 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $40.86 | Resistance | 2.0% above the last close | turned there twice · 2026-05-07 to 2026-09-16 |
| $39.14 | Support | 2.3% below the last close | turned there five times · 2025-06-02 to 2026-02-20 |
| $41.69 | Resistance | 4.1% above the last close | turned there twice · 2025-07-29 to 2026-01-08 |
| $37.74 | Support | 5.8% below the last close | turned there 9 times · 2025-04-08 to 2026-09-23 |
| $42.85 | Resistance | 7.0% above the last close | turned there five times · 2024-10-15 to 2026-08-10 |
| $36.02 | Support | 10.1% below the last close | turned there three times · 2025-12-05 to 2026-05-21 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $38.21.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 4 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 7 trading days, since 2026-09-30.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$60.57 range $55.00 – $72.00; median $59.00
Analyst estimates, as of 2026-10-07. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for VCEL
- Consensus EPS estimate$0.056 next reporting period, as of 2026-10-07
- Estimate change, 30 days$0.00 from $0.056, on 2026-09-01, 36-day window
- Readings revised upward0% of 5 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on a limited number of specialized cell therapy products for the majority of revenue.","Complex, time-sensitive, and strictly regulated manufacturing and supply chain processes for patient-specific therapies.","Significant competition in the orthopedic and burn care markets from larger, well-capitalized medical device and pharmaceutical companies."]
What changed in the latest 10-Q
AI-assisted comparison of VCEL's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- In March 2026, FDA approval was received to begin MACI commercial manufacturing at the Burlington facility (filed 2026-05-07)
- The Company has begun transitioning the Burlington facility's manufacturing component into the primary manufacturing facility for MACI (filed 2026-05-07)
- The Burlington facility's manufacturing component will eventually also become the primary manufacturing facility for Epicel, upon FDA qualification for Epicel manufacturing (filed 2026-05-07)
- More than 900 surgeons have participated in MACI Arthro since its launch (filed 2026-05-07)
- Removed:
- Description of Vericel as 'a fully-integrated, commercial-stage biopharmaceutical company' was removed from Overview section (filed 2025-11-06)
- Tagline 'Whether we are treating damaged cartilage or severe burns, we provide advanced therapies to repair serious injuries and restore lives' was removed (filed 2025-11-06)
- Section titled 'Conflicts in the Middle East' discussing Middle East instability, MediWound facilities in Yavne Israel, and NexoBrid supply concerns was removed (filed 2025-11-06)
- Section titled 'U.S. Trade Policy' discussing tariffs and trade policy impact was removed (filed 2025-11-06)
- Statement that Burlington facility is 'substantially complete' changed to 'complete' (filed 2026-05-07)
- Statement that facility's manufacturing component will 'eventually become' primary facility changed to current transition status (filed 2026-05-07)
- Reworded:
- Manufacturing facility description changed from 'is used for' to 'is currently used for' (filed 2026-05-07)
- Reference to selling 'MACI Arthro instruments' changed from 'the MACI Arthro instruments' (filed 2026-05-07)
- Product portfolio description of Epicel changed from 'Both autologous cell therapy products are currently manufactured' to 'Both autologous cell therapy products, MACI and Epicel, are currently manufactured' for clarity (filed 2026-05-07)
- NexoBrid indication description changed from 'full-thickness burns' to 'full-thickness thermal burns' (filed 2026-05-07)
- Notes:
- The newer filing text appears truncated at the end of the MACI section (ends mid-sentence with 'To date, more than 900 surgeons have participated'), preventing complete comparison of content beyond that point
- Page numbers differ between filings (21-22 in newer vs 23-24 in older), suggesting different document layouts but same section content otherwise
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 5 sells ($1M) — 3 selling insiders
- Last 180 days · read to 2026-10-040 buys · 21 sells ($5M) — 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-12. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about VCEL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding VCEL as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 11,519,818
- Reported value $512,544,667
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 2 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about VCEL's institutional holders → See what each manager we track holds →
Short interest (FINRA)
VCEL had 5,483,102 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
VCEL had 10.7% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.13 days to cover at the same settlement.
- Reported short interest (shares) 5,483,102
- Short interest (% of shares outstanding) 10.7%
- Prior settlement (shares) 4,759,226
- Reported change 15.21%
- Days to cover (reported) 12.13
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare VCEL vs…
VERICEL CORP is found in…
Frequently asked questions
What does VERICEL CORP (VCEL) do?
Vericel is a commercial-stage biopharmaceutical company focused on the development and marketing of advanced cell therapy and regenerative medicine products. The company's primary offerings address the treatment of patients with severe burns and sports-related cartilage injuries through specialized cell-based treatments. Vericel operates integrated manufacturing and commercialization infrastructure to support its proprietary therapeutic pipeline.
What sector is VERICEL CORP (VCEL) in?
VERICEL CORP (VCEL) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are VERICEL CORP's (VCEL) competitors?
Notable peers of VERICEL CORP (VCEL) include Smith & Nephew, Arthrex, Zimmer Biomet and Stryker. This peer set is informational only — not financial advice.
Is VERICEL CORP (VCEL) overbought or oversold right now?
VERICEL CORP (VCEL) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 48, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on VCEL come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.